177 related articles for article (PubMed ID: 28346018)
1. Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.
Rabie H; Decloedt EH; Garcia-Prats AJ; Cotton MF; Frigati L; Lallemant M; Hesseling A; Schaaf HS
Expert Opin Pharmacother; 2017 Apr; 18(6):589-598. PubMed ID: 28346018
[TBL] [Abstract][Full Text] [Related]
2. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
Regazzi M; Carvalho AC; Villani P; Matteelli A
Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis and HIV co-infection: a practical therapeutic approach.
Breen RA; Swaden L; Ballinger J; Lipman MC
Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
[TBL] [Abstract][Full Text] [Related]
4. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
[TBL] [Abstract][Full Text] [Related]
5. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
Schluger NW
Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.
MMWR Recomm Rep; 1998 Oct; 47(RR-20):1-58. PubMed ID: 9809743
[TBL] [Abstract][Full Text] [Related]
7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
8. Medication errors with antituberculosis therapy in an inpatient, academic setting: forgotten but not gone.
Jen SP; Zucker J; Buczynski P; Odenigbo C; Cennimo D; Patrawalla A
J Clin Pharm Ther; 2016 Feb; 41(1):54-8. PubMed ID: 26763664
[TBL] [Abstract][Full Text] [Related]
9. The pharmacological challenges of treating tuberculosis and HIV coinfections.
Egelund EF; Dupree L; Huesgen E; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):213-223. PubMed ID: 27828731
[TBL] [Abstract][Full Text] [Related]
10. No impact of rifamycin selection on tuberculosis treatment outcome in HIV coinfected patients.
Singh R; Marshall N; Smith CJ; Reynolds CJ; Breen RA; Bhagani S; Cropley I; Hopkins S; Swaden L; Johnson MA; Lipman MC
AIDS; 2013 Jan; 27(3):481-4. PubMed ID: 23014518
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.
TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
13. Update on treatment and prevention guidelines for HIV-related tuberculosis.
Chaisson RE
Hopkins HIV Rep; 1999 May; 11(3):3,10,12. PubMed ID: 11367371
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
Burman WJ; Gallicano K; Peloquin C
Clin Infect Dis; 1999 Mar; 28(3):419-29; quiz 430. PubMed ID: 10194057
[No Abstract] [Full Text] [Related]
15. Recurrence of tuberculosis in HIV-1-infected adults treated after rifamycin-based treatment and highly active antiretroviral therapy.
Hung CC; Hsiao CF
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):437-9. PubMed ID: 14615663
[No Abstract] [Full Text] [Related]
16. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
[TBL] [Abstract][Full Text] [Related]
17. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
[TBL] [Abstract][Full Text] [Related]
18. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological interactions between rifampicin and antiretroviral drugs: challenges and research priorities for resource-limited settings.
Semvua HH; Kibiki GS; Kisanga ER; Boeree MJ; Burger DM; Aarnoutse R
Ther Drug Monit; 2015 Feb; 37(1):22-32. PubMed ID: 24943062
[TBL] [Abstract][Full Text] [Related]
20. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
